Aurobindo Pharma’s Subsidiary Facility Classified as Voluntary Action Indicated by US FDA
Aurobindo Pharma Limited announced on March 20, 2026, that Unit-V of Apitoria Pharma Private Limited, a wholly-owned subsidiary, has been classified as ‘Voluntary Action Indicated’ (VAI) by the United States Food and Drug Administration (US FDA).The US FDA inspected the API manufacturing facility, located in Pashamylaram Village, Patancheru Mandal, Sangareddy District, Telangana, from December 1 to December 12, 2025. Following the inspection, a ‘Form 483’ was issued, noting three observations.
The Establishment Inspection Report (EIR) has now classified the facility as VAI, marking the inspection as closed.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.